Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air-blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“Free drugs may fail to reach the desired site of effect with required dose, and the drugs in non-target organs may be associated with undesired side reactions 76 .”
Bellani, G., Laffey, J. G., Pham, T., Fan, E., Brochard, L., Esteban, A., Gattinoni, L., van Haren, F., Larsson, A., McAuley, D. F., et al. (2016) · JAMA · doi:10.1001/jama.2016.0291 · Cited by 5,766
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613 · cited 1×
“The COVID-19 pandemic has sparked new interest in understanding the intricate pathologies of ARDS 12 .”
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990 · cited 1×
“In general, enhanced lung accumulation and uptake by phagocytic cells is correlated to the increase of particle size 67,120 .”
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940 · cited 1×
“The etiologies of ARDS, particularly infections, such as SARS-CoV-2 invasion, can bring about cytokine storms in the pulmonary environment and systemic circulation, severely damaging lung tissues, and account for high mortality 34,35 .”
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912 · cited 2×
“The etiologies of ARDS, particularly infections, such as SARS-CoV-2 invasion, can bring about cytokine storms in the pulmonary environment and systemic circulation, severely damaging lung tissues, and account for high mortality 34,35 .”
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823 · cited 1×
“Since surface hydrophilicity is closely related to the immunomodulatory properties, modifying these factors can reduce possible pro-inflammatory properties of delivery systems and make them suitable drug carriers 128 .”
Acute respiratory distress syndrome
Thompson, B. T., Chambers, R. C., & Liu, K. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608077 · Cited by 1,807 · cited 9×
“…infiltrated inflammatory cells in the alveoli, along with the simultaneously released pro-inflammatory cytokines, chemokines, and other in-flammatory mediators, can damage the pulmonary epithelium and endothelium, causing apoptosis/necrosis of cells and dissolution of the intercellular junctions 3,42 .”
InfluentialMulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818 · cited 1×
“Nanomedicine-based delivery systems have emerged to improve biopharmacokinetic property and therapeutic outcome of drugs 20 .”
Self-citationFang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Exosome‐Guided Phenotypic Switch of M1 to M2 Macrophages for Cutaneous Wound Healing
Kim, H., Wang, S. Y., Kwak, G., Yang, Y., Kwon, I. C., & Kim, S. H. (2019) · Advanced Science · doi:10.1002/advs.201900513 · Cited by 542 · cited 1×
“…nano-formulations could interact with macrophages to enhance the intracellular delivery, and further exert their functions such as regulating negative inflammatory receptors or pro-inflammatory signaling pathways of acute responses, and manipulating macrophage polarization for ARDS therapy 179,180 .”
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532 · cited 3×
“Walls et al. 249 developed protein nanovaccines displaying sixty SARS-CoV-2 Spike RBD, which can induce robust neutralizing antibody responses to target multiple distinct epitopes.”
Cell or Cell Membrane-Based Drug Delivery Systems
Tan, S., Wu, T., Zhang, D., & Zhang, Z. (2015) · Theranostics · doi:10.7150/thno.11852 · Cited by 466
Self-citationMonsel, A., Zhu, Y.-G., Gudapati, V., Lim, H., & Lee, J. W. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1170804 · Cited by 200
Metadata
- Authors
- Qiao, Q., Liu, X., Yang, T., Cui, K., Kong, L., Yang, C., & Zhang, Z.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 11
- Issue
- 10
- Pages
- 3060-3091
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3157841475
- Cited by
- 201
- References
- 19
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.